Considerations in selecting rapid-onset opioids for the management of breakthrough pain

Michael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the i...

Full description

Bibliographic Details
Main Authors: Perelman M, Leake S
Format: Article
Language:English
Published: Dove Medical Press 2013-06-01
Series:Journal of Pain Research
Online Access:http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254
id doaj-22e4a7c2cb4e4f37848a2a84d49c1245
record_format Article
spelling doaj-22e4a7c2cb4e4f37848a2a84d49c12452020-11-25T00:09:31ZengDove Medical PressJournal of Pain Research1178-70902013-06-012013default435436Considerations in selecting rapid-onset opioids for the management of breakthrough painPerelman MLeake SMichael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the identification by Farrar et al2 of a 33% (often ≥2 point) change in the pain intensity difference as a measure of a ‘clinically important improvement’. For these reasons, Smith focuses on the various transmucosal fentanyl formulations that offer a rapid onset and he provides a nice summary of the key features of each of the available products.View original paper by Howard S Smith.http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254
collection DOAJ
language English
format Article
sources DOAJ
author Perelman M
Leake S
spellingShingle Perelman M
Leake S
Considerations in selecting rapid-onset opioids for the management of breakthrough pain
Journal of Pain Research
author_facet Perelman M
Leake S
author_sort Perelman M
title Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_short Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_full Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_fullStr Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_full_unstemmed Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_sort considerations in selecting rapid-onset opioids for the management of breakthrough pain
publisher Dove Medical Press
series Journal of Pain Research
issn 1178-7090
publishDate 2013-06-01
description Michael Perelman, Suzan LeakeArchimedes Pharma, Bedminister, NJ, USAWe read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the identification by Farrar et al2 of a 33% (often ≥2 point) change in the pain intensity difference as a measure of a ‘clinically important improvement’. For these reasons, Smith focuses on the various transmucosal fentanyl formulations that offer a rapid onset and he provides a nice summary of the key features of each of the available products.View original paper by Howard S Smith.
url http://www.dovepress.com/nbspconsiderations-in-selecting-rapid-onset-opioids-for-the-management-a13254
work_keys_str_mv AT perelmanm considerationsinselectingrapidonsetopioidsforthemanagementofbreakthroughpain
AT leakes considerationsinselectingrapidonsetopioidsforthemanagementofbreakthroughpain
_version_ 1725411517326688256